Erdheim-Chester Disease Clinical Trial
Official title:
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes. The investigators also want to learn how these things change over time for people with these conditions. To try to figure this out, doctors would like to collect information about people who have histiocytosis and how they are treated for this disease. Some participants will be asked to complete a brief interview over the telephone. Only a limited number of interviews will take place, and not everyone will be asked to participate in the interview. It is okay if the participant does not want to participate in the interview portion. If this is the case, the participant should let the study team member know when contacted.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06317246 -
Subtypes and Prognostic Factors in Erdheim-Chester Disease
|
N/A | |
| Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
| Recruiting |
NCT05093335 -
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
|
Early Phase 1 | |
| Completed |
NCT02608619 -
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
|
||
| Terminated |
NCT01727206 -
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
|
Phase 2 | |
| Recruiting |
NCT02089724 -
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
|
N/A | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Recruiting |
NCT05768178 -
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06332183 -
GWAS and EWAS in Patients With Erdheim-Chester Disease
|
||
| Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03794297 -
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
|
Phase 2 | |
| Active, not recruiting |
NCT05092815 -
The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
|
Phase 2 | |
| Recruiting |
NCT04079179 -
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
|
Phase 2 |